Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:ACAD NASDAQ:CRSP NASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$4.57-4.2%$4.39$1.89▼$5.82$1.43B0.643.65 million shs4.69 million shsACADACADIA Pharmaceuticals$24.20+1.0%$24.18$13.40▼$26.65$4.04B0.751.85 million shs1.62 million shsCRSPCRISPR Therapeutics$59.07-3.5%$56.97$30.04▼$71.13$5.57B1.811.79 million shs2.76 million shsPTCTPTC Therapeutics$60.65+1.6%$50.97$34.57▼$62.18$4.74B0.531.16 million shs2.26 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics+9.66%+12.50%+3.92%+37.46%+77.99%ACADACADIA Pharmaceuticals-2.88%-3.54%-5.41%+4.40%+48.45%CRSPCRISPR Therapeutics+5.79%+13.97%+2.44%+37.72%+28.17%PTCTPTC Therapeutics+1.20%+2.17%+22.27%+18.36%+76.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$4.57-4.2%$4.39$1.89▼$5.82$1.43B0.643.65 million shs4.69 million shsACADACADIA Pharmaceuticals$24.20+1.0%$24.18$13.40▼$26.65$4.04B0.751.85 million shs1.62 million shsCRSPCRISPR Therapeutics$59.07-3.5%$56.97$30.04▼$71.13$5.57B1.811.79 million shs2.76 million shsPTCTPTC Therapeutics$60.65+1.6%$50.97$34.57▼$62.18$4.74B0.531.16 million shs2.26 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics+9.66%+12.50%+3.92%+37.46%+77.99%ACADACADIA Pharmaceuticals-2.88%-3.54%-5.41%+4.40%+48.45%CRSPCRISPR Therapeutics+5.79%+13.97%+2.44%+37.72%+28.17%PTCTPTC Therapeutics+1.20%+2.17%+22.27%+18.36%+76.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 3.00Buy$8.0075.05% UpsideACADACADIA Pharmaceuticals 2.65Moderate Buy$29.6522.51% UpsideCRSPCRISPR Therapeutics 2.47Hold$71.6021.21% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$69.0013.77% UpsideCurrent Analyst Ratings BreakdownLatest ABCL, CRSP, PTCT, and ACAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025ACADACADIA PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/11/2025ACADACADIA PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $39.009/9/2025ACADACADIA PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $39.009/3/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$118.008/26/2025CRSPCRISPR TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/20/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$79.00 ➝ $73.008/20/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$76.00 ➝ $71.008/20/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$82.00 ➝ $76.008/8/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$70.008/8/2025PTCTPTC TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/8/2025PTCTPTC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$60.00 ➝ $63.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$28.83M47.37N/AN/A$3.58 per share1.28ACADACADIA Pharmaceuticals$957.80M4.26$0.71 per share33.99$4.40 per share5.50CRSPCRISPR Therapeutics$37.31M143.99N/AN/A$22.64 per share2.61PTCTPTC Therapeutics$806.78M5.97N/AN/A($14.24) per share-4.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.550.00N/AN/A-511.88%-16.17%-12.24%11/3/2025 (Estimated)ACADACADIA Pharmaceuticals$226.45M$1.3318.2031.846.0721.80%14.69%9.41%11/5/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$5.430.00N/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.977.87N/AN/A35.65%-106.31%30.61%11/6/2025 (Estimated)Latest ABCL, CRSP, PTCT, and ACAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ABCLAbCellera Biologics-$0.17-$0.12+$0.05-$0.12$7.55 million$17.08 million8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07-$0.83+$0.24-$0.83$173.01 million$178.88 million8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A11.0711.07ACADACADIA PharmaceuticalsN/A2.912.83CRSPCRISPR TherapeuticsN/A16.6116.61PTCTPTC TherapeuticsN/A3.623.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%ACADACADIA Pharmaceuticals96.71%CRSPCRISPR Therapeutics69.20%PTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%ACADACADIA Pharmaceuticals26.50%CRSPCRISPR Therapeutics4.30%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.83 million212.47 millionOptionableACADACADIA Pharmaceuticals510168.71 million124.00 millionOptionableCRSPCRISPR Therapeutics46090.95 million87.04 millionOptionablePTCTPTC Therapeutics1,41079.44 million75.07 millionOptionableABCL, CRSP, PTCT, and ACAD HeadlinesRecent News About These CompaniesPTC Therapeutics (NASDAQ:PTCT) Director Emma Reeve Sells 15,705 Shares4 hours ago | marketbeat.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells 15,705 Shares of StockSeptember 17 at 6:02 AM | insidertrades.comIntech Investment Management LLC Buys 15,167 Shares of PTC Therapeutics, Inc. $PTCTSeptember 17 at 3:08 AM | marketbeat.comBank of America Securities Keeps Their Buy Rating on PTC Therapeutics (PTCT)September 16 at 8:23 PM | theglobeandmail.comPTC Therapeutics (NASDAQ:PTCT) VP Sells $1,382,504.00 in StockSeptember 16 at 5:20 PM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 24,585 SharesSeptember 16 at 5:20 PM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) VP Sells $1,382,504.00 in StockSeptember 16 at 4:33 AM | insidertrades.comPTC Therapeutics, Inc. $PTCT Stake Reduced by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.September 15 at 3:30 AM | marketbeat.comEllsworth Advisors LLC Makes New $588,000 Investment in PTC Therapeutics, Inc. $PTCTSeptember 14 at 5:16 AM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Director David Southwell Sells 12,000 SharesSeptember 13, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Sets New 1-Year High - Here's WhySeptember 13, 2025 | marketbeat.comPTC Therapeutics, Inc. $PTCT Shares Sold by Jacobs Levy Equity Management Inc.September 13, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Director Sells $700,080.00 in StockSeptember 12, 2025 | insidertrades.comBayforest Capital Ltd Purchases New Shares in PTC Therapeutics, Inc. $PTCTSeptember 12, 2025 | marketbeat.comEric Pauwels Sells 39,850 Shares of PTC Therapeutics (NASDAQ:PTCT) StockSeptember 11, 2025 | marketbeat.comPTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKUSeptember 11, 2025 | msn.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 39,850 Shares of StockSeptember 10, 2025 | insidertrades.comAQR Capital Management LLC Boosts Stake in PTC Therapeutics, Inc. $PTCTSeptember 10, 2025 | marketbeat.comCantor Fitzgerald Keeps Their Buy Rating on PTC Therapeutics (PTCT)September 8, 2025 | theglobeandmail.comPTC Therapeutics, Inc. (PTCT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comPTC Therapeutics, Inc. $PTCT Shares Bought by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABCL, CRSP, PTCT, and ACAD Company DescriptionsAbCellera Biologics NASDAQ:ABCL$4.57 -0.20 (-4.19%) Closing price 04:00 PM EasternExtended Trading$4.64 +0.06 (+1.42%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.ACADIA Pharmaceuticals NASDAQ:ACAD$24.20 +0.24 (+1.00%) Closing price 04:00 PM EasternExtended Trading$24.44 +0.24 (+1.00%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.CRISPR Therapeutics NASDAQ:CRSP$59.07 -2.12 (-3.46%) Closing price 04:00 PM EasternExtended Trading$59.49 +0.42 (+0.71%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.PTC Therapeutics NASDAQ:PTCT$60.65 +0.96 (+1.61%) Closing price 04:00 PM EasternExtended Trading$60.66 +0.01 (+0.02%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
